Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
May 30 2024 - 8:30AM
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the
“Company”), a pre-clinical-stage pharmaceutical company focused on
the development and commercialization of Telomir-1 as the first
novel small molecule to lengthen the DNA’s protective telomere caps
as a potential treatment for age-related conditions, today
announced the commencement of several significant milestones. These
events underscore its commitment to advancing innovative treatments
to mitigate the effects of aging and the continuation of its
groundbreaking work.
“Beginning the telomere length and safety study,
it is incredibly important for Telomir as it marks the next phase
in the development of Telomir-1 and we believe should provide us
with information that will help us to make progress in our efforts
to combat many of the diseases of aging,” said Dr. Chris Chapman,
Co-Founder, Chairman, CEO, President and CMO of Telomir. These
studies are potentially usable for veterinary as well as human IND
purposes. “We believe the data from the canine study will provide
us with pre-clinical animal testing endpoints to determine
Telomir-1’s potential as a treatment for age-related conditions
such as gait weakness and joint damage, and will provide us with
information on physical examinations, blood collection, urine
collection, and telomere length.” Dr. Mike Roizen, special
consultant to Telomir reiterated that “the study should not only be
used to support further work on benefits and risks in canines,
especially those with joint disease, but also provide key
information for designing studies in humans.”
Initiation of The Safety of Telomir-1
when Administered Orally to Geriatric Laboratory Beagle Dogs for 63
Consecutive Days StudyOn May 28, 2024, Telomir began a
pivotal study analyzing telomere length to evaluate the aging
process and safety of Telomir-1, in geriatric canines, beginning
with four canines receiving active doses and one canine receiving
placebo doses. Telomir-1 is the Company’s therapeutic candidate
aimed at addressing age-related diseases in humans and animals. We
believe this study represents a crucial step in the Company’s
efforts to develop effective treatments for chronic conditions,
which affects millions of pets and humans alike.
Dosing of Zeus, A Geriatric German
ShepherdIn parallel with the pivotal canine study, the
Company also announced that it is currently using Telomir-1 to
treat Zeus, a 12-year-old German Shepherd. Zeus has completed over
a month of daily dosing. This case will provide valuable insights
and real-world data that will inform its ongoing and future
research and regulatory initiatives which target age-related
diseases, oncology and post-surgery recovery.
About Telomir
Pharmaceuticals, Inc.Telomir Pharmaceuticals, Inc.
(Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company
focused on the development and commercialization of Telomir-1 as
the first novel small molecule to lengthen the DNA’s protective
telomere caps in order to potentially reverse age-related
conditions. Telomeres are the protective end caps of a chromosome
made up of DNA sequences and proteins. As humans age, telomeres
shorten, with metal reactivity accelerating the process, which
presents us with an increased chance of contracting a number of
degenerative and age-related diseases. Telomir’s goal is to develop
and commercialize Telomir-1 (which is proposed to be dosed orally)
for hemochromatosis (iron overload) and ultimately
post-chemotherapy recovery and a broader range of other age-related
inflammatory conditions such as osteoarthritis.
The Nobel Assembly at Karolinska Institute
(Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009
for the discovery of how chromosomes are protected by telomeres and
the enzyme telomerase.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTSThis press release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. These forward-looking statements
include, without limitation, statements regarding completion,
timing and anticipated size of the initial public offering and the
expected commencement of trading on the Nasdaq.
Any forward-looking statements in this press
release are based on Telomir's current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the potential use of
the data from our studies, our ability to develop and commercialize
Telomir-1 and the aging process and safety of Telomir-1 . These and
other risks concerning Telomir's programs and operations are
described in additional detail in its Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, which is on file with
the SEC. Telomir explicitly disclaims any obligation to update
any forward-looking statements except to the extent required by
law.
For further information, please contact:
KCSA Strategic Communications Phil
Carlsontelomir@kcsa.comTelomir
Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Aug 2023 to Aug 2024